Phase 2 Trial Testing Alkahest’s Investigational GRF6019 for Alzheimer’s Doses First Patient

Phase 2 Trial Testing Alkahest’s Investigational GRF6019 for Alzheimer’s Doses First Patient
Alkahest‘s Phase 2 clinical trial testing GRF6019 — an experimental blood-derived protein — in patients with mild to moderate Alzheimer’s disease has dosed its first participant, the company recently announced. The trial (NCT03520998), which will assess the safety, tolerability, and feasibility of GRF6019, is still recruiting participants. Researchers expect to enroll 40 patients. “The initiation of this

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

2 comments

  1. Phillip Nereson says:

    Please consider Phil Nereson for the Phase 2 study. He is in the moderate stage of Alzheimers. He lives in downtown Minneapolis and I am his caregiver, Dorothy Griffore. We are doctoring at Mayo Clinic as a yearly update and just recently met with Dr. Vossel at the University of MN in which he was diagnosed as being in the moderate stage. He is totally open to any test trials that would be available to him. Thank you for your consideration

  2. Leslie Sanqui says:

    My husband was just diagnosed with AD, he is 84 years old and is in the moderate stage. We live in Southern California and he would like to participate on your trial. Please consider him, appreciate your attention. Thank you

Leave a Comment

Your email address will not be published. Required fields are marked *